Anesth Pain Med.  2023 Jan;18(1):21-28. 10.17085/apm.22258.

Mortality scoring systems for liver transplant recipients: before and after model for end-stage liver disease score

• Chung YH
• Jung J
• Kim SH

• KMID: 2540330
• DOI: http://doi.org/10.17085/apm.22258

Abstract

The mortality scoring systems for patients with end-stage liver disease have evolved from the Child-Turcotte-Pugh score to the model for end-stage liver disease (MELD) score, affecting the wait list for liver allocation. There are inherent weaknesses in the MELD score, with the gradual decline in its accuracy owing to changes in patient demographics or treatment options. Continuous refinement of the MELD score is in progress; however, both advantages and disadvantages exist. Recently, attempts have been made to introduce artificial intelligence into mortality prediction; however, many challenges must still be overcome. More research is needed to improve the accuracy of mortality prediction in liver transplant recipients.

Keyword

Acute on chronic liver failure; End-stage liver disease; Liver cirrhosis; Liver transplantation; Mortality; Organ dysfunction scores; Prognosis

Reference

1. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet. 1963; 117:659–76.

2. Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by Child CG: Philadelphia (PA), Saunders. 1964, pp 50-64.

3. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000; 31:864–71.

4. Ge J, Kim WR, Lai JC, Kwong AJ. "Beyond MELD" - emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation. J Hepatol. 2022; 76:1318–29.

5. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo end-stage liver disease. Hepatology. 2001; 33:473–5.

6. Kim MS. Modification of emergency status in deceased donor liver allocation: evidence for Korean model of end-stage liver disease (MELD) system. J Korean Soc Transplant. 2016; 30:51–8.

7. Godfrey EL, Malik TH, Lai JC, Mindikoglu AL, Galván NTN, Cotton RT, et al. The decreasing predictive power of MELD in an era of changing etiology of liver disease. Am J Transplant. 2019; 19:3299–307.

8. Hernaez R, Liu Y, Kramer JR, Rana A, El-Serag HB, Kanwal F. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020; 73:1425–33.

9. Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. J Hepatol. 2011; 54:462–70.

10. Allen AM, Heimbach JK, Larson JJ, Mara KC, Kim WR, Kamath PS, et al. Reduced access to liver transplantation in women: role of height, MELD exception scores, and renal function underestimation. Transplantation. 2018; 102:1710–6.

11. Conn HO. A peek at the Child-Turcotte classification. Hepatology. 1981; 1:673–6.

12. Garcia-Tsao G. The Child-Turcotte classification: from gestalt to sophisticated statistics and back. Dig Dis Sci. 2016; 61:3102–4.

13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60:646–9.

14. Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol. 2011; 54:1297–306.

15. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33:464–70.

16. Freeman RB Jr, Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM. Improving liver allocation: MELD and PELD. Am J Transplant. 2004; 4 Suppl 9:114–31.

17. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002; 8:851–8.

18. Finkenstedt A, Dorn L, Edlinger M, Prokop W, Risch L, Griesmacher A, et al. Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better? Liver Int. 2012; 32:1211–6.

19. Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021; 161:1887–95.e4.

20. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007; 246:502–9; discussion 509-11.

21. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334:693–9.

22. Parikh ND, Singal AG. Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2016; 7:97–100.

23. Huo TI, Lin HC, Lee FY, Hou MC, Lee PC, Wu JC, et al. Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int. 2006; 26:55–61.

24. Yoo HY, Edwin D, Thuluvath PJ. Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am J Gastroenterol. 2003; 98:1395–9.

25. Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020; 69:564–8.

26. Kwong AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, et al. OPTN/SRTR 2019 annual data report: liver. Am J Transplant. 2021; 21 Suppl 2:208–315.

27. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008; 359:1018–26.

28. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006; 130:1652–60.

29. Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology. 2011; 140:1952–60.

30. Biggins SW. Use of serum sodium for liver transplant graft allocation: a decade in the making, now is it ready for primetime? Liver Transpl. 2015; 21:279–81.

31. McDiarmid SV, Anand R, Lindblad AS; Principal Investigators and Institutions of the Studies of Pediatric Liver Transplantation (SPLIT) Research Group. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation. 2002; 74:173–81.

32. SPLIT Research Group. Studies of pediatric liver transplantation (SPLIT): year 2000 outcomes. Transplantation. 2001; 72:463–76.

33. Chang CH, Bryce CL, Shneider BL, Yabes JG, Ren Y, Zenarosa GL, et al. Accuracy of the pediatric end-stage liver disease score in estimating pretransplant mortality among pediatric liver transplant candidates. JAMA Pediatr. 2018; 172:1070–7.

34. Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, APASL ACLF Research Consortium (AARC) for APASL ACLF working Party, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update. Hepatol Int. 2019; 13:353–90. Erratum in: Hepatol Int 2019; 13: 826-8.

35. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology. 2008; 47:1401–15.

36. Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017; 66:541–53.

37. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144:1426–37, 1437.e1-9.

38. Olson JC, Kamath PS. Acute-on-chronic liver failure: concept, natural history, and prognosis. Curr Opin Crit Care. 2011; 17:165–9.

39. Sundaram V, Shah P, Wong RJ, Karvellas CJ, Fortune BE, Mahmud N, et al. Patients with acute on chronic liver failure grade 3 have greater 14-day waitlist mortality than status-1a patients. Hepatology. 2019; 70:334–45.

40. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. CANONIC Study Investigators of the EASL-CLIF Consortium. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015; 62:243–52.

41. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, et al. CANONIC Study Investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014; 61:1038–47.

42. Lau L, Kankanige Y, Rubinstein B, Jones R, Christophi C, Muralidharan V, et al. Machine-learning algorithms predict graft failure after liver transplantation. Transplantation. 2017; 101:e125–32.

43. Ferrarese A, Sartori G, Orrù G, Frigo AC, Pelizzaro F, Burra P, et al. Machine learning in liver transplantation: a tool for some unsolved questions? Transpl Int. 2021; 34:398–411.

44. Banerjee R, Das A, Ghoshal UC, Sinha M. Predicting mortality in patients with cirrhosis of liver with application of neural network technology. J Gastroenterol Hepato. 2003; 18:1054–60.

45. Cucchetti A, Vivarelli M, Heaton ND, Phillips S, Piscaglia F, Bolondi L, et al. Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. Gut. 2007; 56:253–8.

46. Guo A, Mazumder NR, Ladner DP, Foraker RE. Predicting mortality among patients with liver cirrhosis in electronic health records with machine learning. PLoS One. 2021; 16:e0256428.

47. Peloso A, Moeckli B, Delaune V, Oldani G, Andres A, Compagnon P. Artificial intelligence: present and future potential for solid organ transplantation. Transpl Int. 2022; 35:10640.

48. Miller PE, Pawar S, Vaccaro B, McCullough M, Rao P, Ghosh R, et al. Predictive abilities of machine learning techniques may be limited by dataset characteristics: insights from the UNOS database. J Card Fail. 2019; 25:479–83.